NAFLD (Nonalcoholic Fatty Liver Disease)
36
9
11
13
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
2.8%
1 terminated out of 36 trials
92.9%
+6.4% vs benchmark
3%
1 trials in Phase 3/4
15%
2 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (36)
Accurate Point of Care Liver Disease Diagnostics (Phase 2)
Shared Pathways Between Non-Alcoholic Fatty Liver Disease and Psoriatic Disease With Guselekumab Therapy
Tocotrienol Against the Progression of End Stage Liver Disease
A Study Between Dapagliflozin and Empagliflozin Effect on NAFLD in Patients With Type 2 Diabetes.
Measuring Amino Acid and Glucose Metabolism in Healthy Volunteers and NAFLD Patients Using Total-body PET
A Trial to Evaluate the Efficacy, Safety, PK, and PD of HP515 in Non - Alcoholic Fatty Liver Disease ( NASH/MASH )
Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis
A Community-based Prospective Cohort Study on Metabolic Dysfunction-Associated Fatty Liver Disease in Older Adults: From Metabolic Trajectories to Extrahepatic Outcomes
Chrononutrition/ Chronotoxicity Intervention in People With Metabolic-associated Steatotic Liver Disease.
Is There a Relationship Between Uric Acid Level and Liver Fibrosis in Obese Patients
PolyCystic Ovary Syndrome as Suggested Risk Group for Non-Alcoholic Fatty Liver Disease
a Safety, Tolerability, and Pharmacokinetic Trial of Multiple Subcutaneous Injections of B1344 Injection in Patients With Nonalcoholic Fatty Liver Disease（NAFLD）
The Impact of Pectin Supplementation on Systematic Inflammation Pathway, Gut Microbiome, and Metabolic Health in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Digital Early Warning System for Acute Lung Injury in Liver Surgery
Integrating Metabolic and Vascular Sensors to Monitor Cardiometabolic Disorders After Nutrition Interventions
OneSTOP (One-Stop Telehealth Obesity Program) for Multidisciplinary Weight Management and Related Comorbidities
Efficacy of Sodium Glucose Cotransporter 2 Inhibitors on Non-Alcoholic Fatty Liver Disease
Manual Therapy in Metabolic Liver Disease
Raspberry Ketone Intake Upregulates Circulating FGF21 and Induces Energy Expenditure in Humans
Studying Non Alcoholic Fatty Liver Disease and Liver Fibrosis Among Systemic Lupus Erythematosus Patients At Assiut University Hospital